WO/2014/117228 TEA FERMENTATION METHOD AND DEVICE FOR IMPLEMENTING SAME||WO||07.08.2014|
||PCT/AZ2013/000002||PASHAYEV, Arif Mirjalal||PASHAYEV, Arif Mirjalal|
The invention relates to the food industry, to medicine and to agriculture, and specifically to a tea fermentation process for use in the processing of cultivated and wild plant raw material. The fermentation method includes subjecting the raw material to an ozone-air mixture, having an ozone concentration of 0.03-0.04 ppm (0.06-0.08 mg/m), at a relative humidity of 95-98% and a temperature of 22-24°С for a period of 40-50 minutes under conditions of operational control over the condition of the product. The device for implementing the fermentation method comprises coaxially arranged electrodes connected to a high voltage source and, between said electrodes, a dielectric barrier in the form of a tubular ozonizer, flexible tubing for inputting the ozone-air mixture, and a humidifying temperature controller which provides for the relative humidity and temperature in the fermentation chamber. Subjecting the raw material to the ozone-air mixture results in an increase in fermentation process output and in the qualitative indicators of the final product.
WO/2014/114706 COMPOSITIONS CONTAINING CHONDROITIN SULPHATE, PROTEOLYTIC ENZYMES AND SULPHYDRYL COMPOUNDS FOR IMPROVING THE BIOAVAILABILITY OF CHONDROITIN SULPHATE||WO||31.07.2014|
||PCT/EP2014/051308||GNOSIS S.P.A.||MIRAGLIA, Niccolò|
The present invention describes combinations comprising chondroitin sulphate (CS), one or more enzymes or enzymatic mixtures possessing proteolytic activity, and sulphydryl compounds, for the treatment and prevention of osteoarthritis and correlated acute and chronic inflammatory processes, or as nutraceutical compositions for the maintenance of musculoskeletal well-being in humans and animals. The characteristic of said combinations is that they increase the intestinal absorption of CS when administered orally. The effect of said combinations is exerted on a wide range of molecular weights of CS, including CS samples with very low molecular weights which already possess greater bioavailability than samples with a higher molecular weight. The effect is exerted on CS samples of any origin.
WO/2014/102818 NOVEL QUINOLONE DERIVATIVES||WO||03.07.2014|
||PCT/IN2013/000796||CADILA HEALTHCARE LIMITED||DESAI, Ranjit, C.|
The present invention relates to novel compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. [Formula should be inserted here].
WO/2014/104894 UREA SYNTHESIS PROCESS AND PLANT||WO||03.07.2014|
||PCT/NL2013/050961||STAMICARBON B.V.||BUITINK, Fredericus Henricus Maria|
Disclosed is a urea plant comprising an additional reactor. With reference to the regular components of a urea plant, including a recovery section and a high pressure carbamate condenser, the additional reactor is positioned between the recovery section and the high pressure carbamate condenser. The invention also relates to a process for the synthesis of urea, comprising an additional reaction step converting, at an earlier stage than conventional, recovered carbamate into urea.
WO/2014/094844 LOCALIZED DISINFECTION SYSTEM FOR LARGE WATER BODIES||WO||26.06.2014|
||PCT/EP2012/076170||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN, Fernando Benjamin|
The present disclosure relates to a method for controlling the microbiological properties of a portion of water within a large body of water by treating such zone with chemical agents, according to the temperature of the water, its salinity, its dilution power and the diffusion of chemicals within the large water body.
WO/2014/094839 USE OF PIDOTIMOD TO TREAT ATOPIC DERMATITIS||WO||26.06.2014|
||PCT/EP2012/076086||POLICHEM S.A.||MAILLAND, Federico|
The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat atopic dermatitis. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, is preferably administered topically.
WO/2014/094840 USE OF PIDOTIMOD TO TREAT PSORIASIS||WO||26.06.2014|
||PCT/EP2012/076088||POLICHEM S.A.||CASERINI, Maurizio|
The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat psoriasis. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either systemically or topically.
WO/2014/095700 NOVEL COMPOUNDS||WO||26.06.2014|
||PCT/EP2013/076672||CHIESI FARMACEUTICI S.P.A.||ALCARAZ, Lilian|
This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.
WO/2014/099676 CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES FAVOURED BY INSUFFICIENT MUCOSAL HYDRATION||WO||26.06.2014|
||PCT/US2013/075108||PARION SCIENCES, INC.||JOHNSON, Michael R.|
This invention provides compounds of the formula (I) and their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.
WO/2014/096378 SATURATED NITROGEN AND N-ACYLATED HETEROCYCLES POTENTIATING THE ACTIVITY OF AN ACTIVE ANTIBIOTIC AGAINST MYCOBACTERIA||WO||26.06.2014|
||PCT/EP2013/077732||UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2||WILLAND, Nicolas|
The present invention concerns a compound of general formula (I) in which n = 0 or 1, R1 represents an optionally substituted alkyl chain, in particular substituted with fluorine, X is chosen from N and CH, and R2 is chosen from phenyl and optionally substituted benzyl, and the heterocycles having 6 vertices comprising one, two or three nitrogen atoms. The present invention also concerns the use of this compound as a drug, in particular in the treatment of bacterial and mycobacterial infections such as tuberculosis in combination with an antibiotic that is active against bacteria and/or mycobacteria, said compound potentiating the activity of said antibiotic.